CAU
GILD icon

Caxton Associates (UK)’s Gilead Sciences GILD Stock Holding History

Caxton Associates (UK)’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$201K Sell
1,441
-548,559
-100% -$76.8M ﹤0.01% 725
2025
Q4 		$67.5M Buy
+550,000
New +$66.8M 1.32% 14
2025
Q2 		– Sell
-5,013
Closed -$562K – 770
2025
Q1 		$562K Buy
+5,013
New +$517K 0.02% 451

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Caxton Associates (UK)'s GILD Position: Q1 2026 in Review

Caxton Associates (UK) reduced its Gilead Sciences (GILD) stake by 100% in Q1 2026, selling an estimated $76.8M and leaving 1,441 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #725.

Caxton Associates (UK) first reported a position in GILD in Q1 2025 and has held it in 3 quarters since. The position peaked at $67.5M in Q4 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Caxton Associates (UK) held 1,441 shares of Gilead Sciences worth $201K as of Q1 2026.
  • Caxton Associates (UK) sold 548,559 Gilead Sciences shares in Q1 2026, an estimated $76.8M.
  • Gilead Sciences made up ﹤0.01% of Caxton Associates (UK)'s portfolio in Q1 2026, its #725 holding.
  • Caxton Associates (UK) first reported a position in Gilead Sciences in Q1 2025 and has held it in 3 quarters since.
  • Caxton Associates (UK)'s Gilead Sciences position peaked at $67.5M in Q4 2025.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.